Biotech | April 08, 2022
Essent Biologics launches Wharton's jelly-derived human mesenchymal stromal cells
Essent continues to broaden its highly characterized, low passage primary cell catalog
Essent continues to broaden its highly characterized, low passage primary cell catalog
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Dupixent peak sales ambition raised to more than €13 billion
Company expects strong organic growth in sales, EBITDA in 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Subscribe To Our Newsletter & Stay Updated
